Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Q32 Bio (QTTB) Long-Term Debt Issuances (2023 - 2024)

Q32 Bio's quarterly Long-Term Debt Issuances came in at $7.0 million in Q1 2024, up 27.27% quarter-over-quarter from $5.5 million in Q3 2023.

Q32 Bio has reported Long-Term Debt Issuances for 2 years, with the latest figure at $7.0 million in Q1 2024.

  • For the quarter ending Q1 2024, Long-Term Debt Issuances changed N/A year-over-year to $7.0 million; the trailing twelve-month figure through Dec 2024 stood at $7.0 million (up 27.27% YoY), and the FY2024 full-year result was $7.0 million, up 27.27% from the prior year.
  • Long-Term Debt Issuances for Q1 2024 stood at $7.0 million, up from $5.5 million in the prior quarter.
  • The five-year high for Long-Term Debt Issuances was $7.0 million in Q1 2024, with the low at $5.5 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Q32 Bio 162.94 Mn 112.19 Mn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 7.00 Mn
Mar 31, 2024 7.00 Mn
Sep 30, 2023 5.50 Mn
Sep 30, 2023 5.50 Mn